VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Sees Large Decrease in Short Interest

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) saw a significant decrease in short interest during the month of January. As of January 30th, there was short interest totaling 2,036,211 shares, a decrease of 16.6% from the January 15th total of 2,441,031 shares. Based on an average daily volume of 1,051,059 shares, the days-to-cover ratio is currently 1.9 days. Approximately 5.3% of the shares of the company are short sold. Approximately 5.3% of the shares of the company are short sold. Based on an average daily volume of 1,051,059 shares, the days-to-cover ratio is currently 1.9 days.

VistaGen Therapeutics Stock Up 4.8%

Shares of VistaGen Therapeutics stock traded up $0.02 during mid-day trading on Tuesday, reaching $0.53. 1,587,603 shares of the stock traded hands, compared to its average volume of 1,322,361. The business has a 50-day moving average of $1.09 and a 200 day moving average of $2.79. The stock has a market capitalization of $21.00 million, a PE ratio of -0.28 and a beta of 0.33. VistaGen Therapeutics has a fifty-two week low of $0.43 and a fifty-two week high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.06. The firm had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.14 million. On average, equities research analysts expect that VistaGen Therapeutics will post -1.77 EPS for the current fiscal year.

Key VistaGen Therapeutics News

Here are the key news stories impacting VistaGen Therapeutics this week:

• Negative Sentiment: Multiple firm reminders that purchasers of VTGN between April 1, 2024 and Dec. 16, 2025 have until March 16, 2026 to seek lead-plaintiff status in a securities fraud suit. VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit
• Negative Sentiment: Rosen Law Firm issues a public reminder about the March 16, 2026 lead-plaintiff deadline for VTGN class action claims. ROSEN Encourages Vistagen Investors to Secure Counsel
• Negative Sentiment: Bernstein Liebhard LLP notes a securities class action has been filed against Vistagen covering the same class period and invites investor participation. Bernstein Liebhard Announces Class Action
• Negative Sentiment: Holzer & Holzer warns investors of the March 16 deadline and highlights allegations that defendants misrepresented or failed to disclose material risks tied to the PALISADE-3 fasedienol trial. Holzer & Holzer Reminder
• Negative Sentiment: DJS Law Group issues a notice that Vistagen is being sued for alleged securities violations and invites affected investors to contact the firm. DJS Law Group Notice
• Negative Sentiment: Schall Law Firm reminder to VTGN investors about the class period and March 16 deadline; repeats allegations of securities law violations. Schall Law Firm Reminder
• Negative Sentiment: Another Rosen Law Firm release echoing the lead-plaintiff deadline and potential contingency-fee recovery for class members. Rosen – Top Ranked Firm Release
• Negative Sentiment: Bronstein, Gewirtz & Grossman urges investors to act after a class action was filed alleging investor harm; reiterates lead-plaintiff deadline. Bronstein Urges Investors to Act
• Negative Sentiment: Schall Law Firm (GlobeNewswire) duplicate reminder emphasizing alleged SEC-rule violations and the March 16 deadline. Schall – GlobeNewswire
• Negative Sentiment: Faruqi & Faruqi reminder about the approaching lead-plaintiff deadline and contact details for potential class participants. Faruqi & Faruqi Reminder
• Negative Sentiment: Portnoy Law Firm announces a class action on behalf of Vistagen investors and details the class period and March 16 deadline. Portnoy Law Firm Announcement
• Negative Sentiment: Earlier Rosen releases reiterating contingency-fee counsel availability for affected VTGN shareholders. Rosen – Skilled Investor Counsel

Institutional Trading of VistaGen Therapeutics

Several large investors have recently bought and sold shares of the business. OMERS ADMINISTRATION Corp purchased a new position in VistaGen Therapeutics in the 4th quarter worth approximately $68,000. State Street Corp grew its position in shares of VistaGen Therapeutics by 25.0% in the fourth quarter. State Street Corp now owns 121,114 shares of the company’s stock valued at $80,000 after purchasing an additional 24,256 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of VistaGen Therapeutics by 123.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 151,874 shares of the company’s stock valued at $101,000 after purchasing an additional 83,857 shares during the last quarter. AdvisorShares Investments LLC lifted its position in VistaGen Therapeutics by 20.9% during the fourth quarter. AdvisorShares Investments LLC now owns 250,188 shares of the company’s stock worth $166,000 after buying an additional 43,190 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in VistaGen Therapeutics by 18.3% during the fourth quarter. Geode Capital Management LLC now owns 352,836 shares of the company’s stock worth $234,000 after buying an additional 54,556 shares during the last quarter. Hedge funds and other institutional investors own 78.39% of the company’s stock.

Analyst Ratings Changes

VTGN has been the topic of several analyst reports. Wall Street Zen raised VistaGen Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. William Blair reaffirmed a “market perform” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of VistaGen Therapeutics in a report on Wednesday, January 21st. Stifel Nicolaus cut shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price objective for the company. in a report on Wednesday, December 17th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $0.90 target price (down from $15.00) on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $0.95.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.